In addition, our study investigated the anti-tumor effect induced by the interaction of immune cells within mouse model when simultaneously treating with the EZH2 degrader and the immune checkpoint inhibitor, anti-PD-1, and elucidating the underlying mechanisms. Here, PDCD1 is linked to neoplasm.